Cabazitaxel injection - Allergan

Drug Profile

Cabazitaxel injection - Allergan

Alternative Names: Cabazitaxel - Allergan

Latest Information Update: 23 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Aug 2015 Actavis receives tentative NDA approval of Cabazitaxel injection for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA
  • 17 Mar 2015 Actavis acquires Allergan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top